Ahmedabad: Intas Pharma has announced the appointment ofAkash Kalal as General Manager – API Production. The company shared the update in a recent LinkedIn post, highlighting Kalal’s extensive experience in pharmaceutical production and operations management. Prior to joining Intas, Kalal served as Site Operation Head at SPC Lifesciences. Over the course of his career, he has held key roles at several major pharmaceutical companies, including Macleods Pharmaceuticals, Lupin, Ranbaxy, Symbiotec Pharma, and Dishman Pharmaceutical & Chemicals Ltd. Intas is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities. Read also:Intas Pharma appoints Dr Ajay Kumar Handa as new Executive Vice President - RnD
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!